GLOBAL LIVER INSTITUTE
In April, GLI Program Director Kristin Hatcher was invited to engage with patient advocacy groups, industry partners, and patients during the PBC Foundation’s International Summit in Edinburgh, Scotland.
At the Academy of Managed Care Pharmacy meeting on April 16, experts discussed the emerging landscape of NASH treatments, focusing on the recent approval of Madrigal’s Rezdiffra.
GLI applauds the announcement of a federally-funded study by the Agency for Healthcare Research and Quality (AHRQ) to assess the prevalence of fatty liver disease (known as metabolic-associated fatty liver disease or nonalcoholic fatty liver disease) as well as its associated costs and barriers in the US.
We extend our deepest gratitude to Dr. Jennifer Guy, Dr. Anjana Pillai, Dr. Christopher Rose, Dr. Elliot Tapper, patient advocate Bruce Dimming, and our sponsors. In case you missed it, our webinar ‘Liver Cancer Care: Management of Hepatic Encephalopathy, Ascites, and Portal Hypertension’ is available on GLI’s YouTube channel! Whether you’re a patient, caregiver, or healthcare professional, this webinar offers guidance and education to improve liver care.
The entire field of liver health has experienced an incredible loss. It is with great sadness that Global Liver Institute, our Liver Action Network members and the patient community express our deepest sorrow on the sudden passing of Dr Stephen Harrison. Our condolences and prayers are with Dr. Harrison’s family, friends and loved ones.
Organ transplantation has revolutionized modern medicine, offering a beacon of hope for individuals battling end-stage organ failure. At the same time, it is intricately entwined with legal and policy frameworks governing procurement, allocation, and ethical considerations. From national regulations to international collaborations, addressing healthcare disparities and combating systemic injustices are vital to providing equal access to lifesaving procedures.
After a brief weekend shutdown, Congress passed the FY 2024 appropriations bills and President Joe Biden signed the $1.2 trillion government funding package on March 23, 2024, closing the books on fiscal year (FY) 2024 appropriations.
Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S.
This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development.
This landmark announcement from the White House follows ongoing advocacy efforts, including a letter to President Joe Biden sent by Prevent Cancer Foundation, GLI, and 80 other advocacy groups to establish Cancer Prevention and Early Detection Month.
Maintaining optimal liver health is crucial, given the liver’s pivotal role as a major detoxifying organ. The liver, being a primary filter of toxins and chemicals that pass through the body, is influenced by an individual’s dietary choices.
Our press kit explains the core facts of the GLI, the Resmetirom launch, and why it’s important (especially to patients) to journalists/reporters/the media in a neat, digestible package.
